Skip to content
Screener

BioMarin Pharmaceuticals BMRN Q2 2025 earnings

Reported August 4, 2025 · After market close

Revenue$825.4MBeat by $63.5M
EPS$1.44Beat by $0.58
Revenue estimate$761.9M
EPS estimate$0.86

Next report

Oct 26, 2026 (in a month)
Revenue estimate$1.0B
EPS estimate$1.35

Financials

Q2 2025

Income statement

See full
Revenue$825.4M+15.9%
Gross profit$675.3M+16.1%
Operating income$276.9M+130%
Net income$240.5M+124%
EPS (diluted)$1.23+124%

Balance sheet

See full
Cash & equivalents$1.2B+24.9%
Total debt$600.0M-62.4%
Total equity$6.0B+14.0%
Total assets$7.5B+5.5%

Cash flow

See full
Operating cash flow$185.3M+56.0%
CapEx$17.1M-19.8%
Free cash flow$168.2M+72.6%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$10.49B-32.9%
Enterprise value$9.87B-39.3%
P/E16×-45.0×
P/S3.4×-2.6×

Profitability

See full
Gross margin79.6%-0.3pp
Operating margin25.3%+15.0pp
Net margin21.5%+11.5pp
FCF margin22.7%—

Returns & leverage

See full
Return on equity11.6%+6.5pp
Debt / equity0.1×-0.2×
Current ratio5.6×+2.5×

Segments

By product

See full
VOXZOGO$221.4M+20.4%
VIMIZIM$215.4M+21.0%
NAGLAZYME$128.9M-2.4%
PALYNZIQ$105.9M+20.0%
ALDURAZYME$56.4M+46.4%

By segment

See full
Reportable Segment$825.4M+15.9%

FAQ

When did BioMarin Pharmaceuticals report Q2 2025 earnings?
BioMarin Pharmaceuticals (BMRN) reported Q2 2025 earnings on August 4, 2025 after market close.
What were BioMarin Pharmaceuticals's Q2 2025 revenue and EPS?
BioMarin Pharmaceuticals reported revenue of $825.4M and eps of $1.44 for Q2 2025.
Did BioMarin Pharmaceuticals beat estimates in Q2 2025?
Revenue beat the consensus estimate of $761.9M by $63.5M. EPS beat the consensus estimate of $0.86 by $0.58.
How did BioMarin Pharmaceuticals's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 16.5% from $708.7M a year earlier and eps grew 50.0% from $0.96.
Where can I find BioMarin Pharmaceuticals's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001048477-25-000086) and the 10-Q periodic report (0001048477-25-000090) directly on SEC EDGAR. The filing index links above go to sec.gov.